ArticleCancer biology & therapy2018

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Laurence Booth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.